Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NALIRIFOX
- Development stage
- Phase 2
- Lead developer
- Ipsen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
NALIRIFOX is a chemotherapy regimen used as a first-line treatment for metastatic pancreatic adenocarcinoma. It consists of four drugs administered together: - Liposomal irinotecan (Onivyde), a topoisomerase I inhibitor encapsulated in liposomes to prolong circulation and enhance tumor delivery. - Oxaliplatin, a platinum-based alkylating agent that forms DNA cross-links. - Fluorouracil (5-FU), an antimetabolite that disrupts DNA synthesis. - Leucovorin (folinic acid), which enhances the effects of 5-FU and protects healthy cells. The key distinction between NALIRIFOX and the similar FOLFIRINOX regimen is the use of liposomal irinotecan instead of standard irinotecan, resulting in improved pharmacokinetics and potentially reduced toxicity. The combination was approved by the FDA in February 2024 and by EMA in March 2024 for first-line treatment of metastatic pancreatic cancer. Clinical trials demonstrated improved overall survival compared to gemcitabine plus nab-paclitaxel[1][2][3][4][5][7].
- Brand names
- NALIRIFOX
- Other names
- FOLFOXIRINALIRIFOX
02
Targets
DNATS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on NALIRIFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NALIRIFOX.